Stockscreener 앱 받기
1.50
0.67%
0.01
시간 외 거래:
1.50
전일 마감가:
$1.49
열려 있는:
$1.5
하루 거래량:
2.79M
Relative Volume:
0.71
시가총액:
$468.48M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-5.5556
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+8.70%
1개월 성능:
+23.97%
6개월 성능:
+32.74%
1년 성능:
+80.53%
1일 변동 폭
$1.475
$1.55
1주일 범위
$1.32
$1.65
52주 변동 폭
$0.515
$1.90
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.50 | 465.36M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Eyes a Breakout Year as It Takes Center Stage at JPM Healthcare - MyChesCo
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference - Ocugen, Inc.
Is Social Media Now Defining Ocugen's (OCGN) Gene Therapy Investment Story More Than Its Science? - Yahoo Finance UK
How Ocugen Inc. stock performs in stagflation2025 Year in Review & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Trend Report: Can Ocugen Inc. (2H51) stock sustain revenue momentumStock Surge & Detailed Earnings Play Alerts - ulpravda.ru
Can Ocugen Inc. (2H51) stock sustain revenue momentumRecession Risk & AI Driven Stock Price Forecasts - ulpravda.ru
Ocugen Inc Is Exploding Again: Hidden Gem or Total Meme Stock? - AD HOC NEWS
Can Ocugen Inc. stock withstand economic slowdownSector Performance Review & Low Risk Wealth Plans - ulpravda.ru
Ocugen Shares Surge Ahead of Pivotal Clinical Data Release - AD HOC NEWS
Ocugen’s Pivotal Year: Clinical Milestones and Financial Runway Define 2026 Outlook - AD HOC NEWS
Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments - Seeking Alpha
Could Ocugen Offer A Vision Of Growth With 2026 Catalysts Approaching? - RTTNews
Ocugen Shares Face Pressure Following Strong Advance - AD HOC NEWS
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MSN
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Market Outlook: Can Pharmaron Beijing Co Ltd 17Q1 stock expand revenue streamsQuarterly Investment Review & Expert Approved Momentum Trade Ideas - moha.gov.vn
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen’s Pivotal Year: Clinical Data and Financial Runway in Focus - AD HOC NEWS
Ocugen stock surges 75% year to date: What's in store for 2026? - MSN
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen’s Gene Therapy Pipeline Drives Investor Optimism - AD HOC NEWS
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? - The Globe and Mail
Ocugen Shares Test Critical Technical Floor - AD HOC NEWS
Ocugen Sees Unusually High Options Volume (NASDAQ:OCGN) - MarketBeat
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Shares Navigate Year-End Consolidation Phase - AD HOC NEWS
Ocugen Inc. Stock Falls Tuesday, Underperforms Market - 富途牛牛
Ocugen’s Pipeline Progress: Targeting Unmet Needs in Rare Eye Diseases - AD HOC NEWS
Is Ocugen’s (OCGN) Rare Disease Summit Spotlight Reframing Its Gene Therapy Investment Narrative? - Yahoo Finance
Is Ocugen (OCGN) Quietly Reframing Its Risk Profile Around Rare Disease Gene Therapies? - simplywall.st
Why Ocugen Inc. stock is a must watch in 2025Energy Sector Updates & Achieve Triple Digit Returns - bollywoodhelpline.com
Why Ocugen Inc. (2H51) stock stays on top picksOptions Play & Community Verified Trade Signals - Улправда
Can Ocugen Inc. stock weather global recession2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Bear Alert: Can Ocugen Inc. stock weather global recessionJuly 2025 Weekly Recap & Risk Managed Investment Strategies - Улправда
Will Ocugen Inc. stock deliver strong dividend growth2025 Macro Impact & Verified Trade Idea Suggestions - Улправда
Ocugen Ties CEO Compensation to Regulatory and Stock Performance - AD HOC NEWS
Is Ocugen Inc. (2H51) stock dividend growth reliable2025 Trading Volume Trends & Technical Entry and Exit Tips - DonanımHaber
Why Ocugen Inc. (2H51) stock is listed among top recommendationsMarket Performance Summary & Weekly Consistent Profit Watchlists - DonanımHaber
Will Ocugen Inc. stock maintain growth story2025 Risk Factors & Low Drawdown Trading Strategies - DonanımHaber
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Grants CEO New Performance-Based Equity Award - TipRanks
Pharma News: Why Ocugen Inc. stock is a must watch in 2025July 2025 Summary & Risk Adjusted Buy and Sell Alerts - Улправда
Why pension funds invest in Ocugen Inc. (2H51) stockAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Ocugen Shares Face Mounting Pressure Amid Financial Concerns - AD HOC NEWS
Ocugen Inc. Stock Rises Tuesday, Outperforms Market - 富途牛牛
Ocugen Inc. Stock Rises Monday, Outperforms Market - 富途牛牛
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - Nasdaq
Ocugen (NASDAQ:OCGN) Shares Up 1.5%What's Next? - MarketBeat
How The Latest Analyst Shifts Are Reshaping Ocugen’s Story and Valuation - Yahoo Finance
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
자본화:
|
볼륨(24시간):